Skip to main content
Premium Trial:

Request an Annual Quote

Nilogen Oncosystems, Scailyte Partner to Improve Precision Cancer Drug Development

NEW YORK – Cancer drugmaker Nilogen Oncosystems this week said it has partnered with Scailyte, a firm discovering biomarkers using single-cell machine learning, to bolster the success of its therapy development programs and advance personalized treatments.

The partners will integrate Nilogen's 3D-Explore tumoroid technology, which creates tumor models from fresh patient samples while preserving the tumor microenvironment, and Scailyte's ScaiVision machine-learning platform, which can detect molecular signatures associated with therapeutic response from single-cell sequencing data. These integrated platforms will allow Tampa, Florida-based Nilogen to sharpen its view of drug-tumor interactions, understand the mechanism of action of investigational agents, and identify best responders to enroll in drug trials.

"[O]ur integrated solutions will not only support our biopharma clients for faster, data-driven decision making throughout their drug development process but will also allow us to advance precision medicine applications for the treatment of cancer patients," Nilogen CSO Soner Altiok said in a statement.

Nilogen, founded in 2013, is focused on developing effective cancer drugs in trials that are less likely to fail and are lower cost. Scailyte, based in Basel, Switzerland, is a spinout of ETH Zurich and combines machine learning and single-cell sequencing data to improve diagnosis and identify predictive biomarkers.